Tagged With "Ironman Coeur d Alene"
Blog Post
18 Senators Sign Gillibrand-Sheehan “Dear Colleague” Letter Supporting the National Asthma Control Program!
Thanks to your efforts, 18 senators signed onto a “Dear Colleague” letter requesting support for a $30-million appropriation in fiscal year 2019 for the National Asthma Control Program (NACP) at the Centers for Disease Control and Prevention (CDC).
Blog Post
3 Ways Humidity Affects Asthma
Allergens, chemicals and strong scents are common triggers for the almost 25 million Americans with asthma. But high humidity can be just as troublesome. People with asthma have inflamed airways that are sensitive to things that may not bother other people. That’s why humidity, and all that comes with it, can be a problem for people with asthma. 1 Here are some reasons why. 1. Humid air feels harder to breathe in. Some believe moist air is heavier and harder to breathe. Heat and humidity...
Blog Post
AAFA Applauds DOT Warning About Denial of Preboarding to Family With Food Allergies
AAFA applauds the warning the U.S. Department of Transportation (USDOT) issued to American Airlines in response to American Airline’s denial of the right to pre-board a family of a child with food allergies. However, AAFA calls on the USDOT and Congress to take even stronger actions to protect the rights of airline passengers with allergies and all disabilities.
Blog Post
AAFA Explains: Can Herbal Supplements Help My Nasal Allergies?
When new drugs and medical procedures are developed, they go through rigorous scientific study. Complementary Alternative Medicine treatments usually do not go through the same type of research. As a result, whether it works (called efficacy) is unproven for most treatments. Most herbal remedies for rhinitis fall into that category.
Blog Post
AAFA Explains: Can Vitamin D Help My Asthma?
With all the benefits vitamin D is thought to have, can it help your asthma? Here’s what you need to know.
Blog Post
AAFA Explains: What Is the Difference Between Alternative and Complementary Medicine?
What is the difference between alternative, complementary and integrative medicine? The Asthma and Allergy Foundation of America (AAFA) wants you to know what these mean so that you can make informed healthcare choices. Complementary medicine refers to something you do or take along with treatment your doctor tells you to follow. Alternative medicine refers to something you do or take instead of your regular treatment. Integrative health care is the practice of combining complementary and...
Blog Post Featured
Plea to the Department of Health and Human Services: People With Allergies Need Access to Epinephrine Now
Manufacturing and insurance issues have made it hard for many members of our community to fill their prescriptions for epinephrine auto-injectors in recent months. But the drug epinephrine itself is not in short supply. This has become a serious concern for families of children with life-threatening food allergies. When families who manage food allergies are in fear for their children's lives because they can't get the medicine they need, our system is broken.
Blog Post
AAFA Mourns the Passing of Congressman Elijah Cummings, Asthma and Allergy Advocate
On Oct. 17, 2019, Representative Elijah Cummings (D-MD) passed away. Representative Cummings was an influential voice in support of people with asthma and allergies.
Blog Post
Act Now to Help Protect National Asthma Control Program
Congress just cleared its final fiscal year 2018 spending bill. The bill included $29 million for the National Asthma Control Program (NACP). This program is run by the Centers for Disease Control and Prevention (CDC). This important action reverses the president's proposed cut of nearly $4 million to the program. And it actually gives a slight increase to the NACP above what the program got in the 2017 fiscal year.
Blog Post
Ask Your Senators to Approve Increased Funding for the National Asthma Control Program
Happy 20th Birthday to the National Asthma Control Program (NACP) of the Centers for Disease Control and Prevention (CDC)! We are thrilled to see that our advocacy efforts are paying off. We applaud the House Appropriations Committee for approving the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill, 2020 today to increase to program funding to $34 million. We hope the Senate will do the same.
Blog Post
Asthma and Allergy Caucus to FDA: Take Action to Prevent Albuterol Shortages
Congressmen Eliot L. Engel (D-NY) and Fred Upton (R-MI), Co-Chairs of the Asthma and Allergy Caucus, joined by Congressmen TJ Cox (D-CA) and Peter King (R-NY), Members of Caucus, led 57 Members of the House on a letter to the Food and Drug Administration (FDA) about shortages of albuterol inhalers, which are critical to effective asthma management.
Blog Post
Asthma and Allergy Research Review, April-June 2017
The Asthma and Allergy Foundation of America will recap some of the top research on allergies and asthma every quarter. Here is a look at studies reported between April and June 2017. Learn why some children may not respond to asthma treatments, how testosterone may affect asthma and more.
Blog Post
Asthma and Allergy Research Review January-March 2017
The Asthma and Allergy Foundation of America will recap some of the top research about allergies and asthma every three months. Here is a look at studies reported between January and March. Read about how treating homes for cockroaches can improve children's asthma, a possible link between insomnia and developing asthma, the safety of allergy immunotherapy and more.
Blog Post
Clean Economy Act Would Benefit Millions of People With Asthma and Allergies by Addressing Climate Crisis
U.S. Senator Tom Carper (D-Del.), top Democrat on the U.S. Senate Environment and Public Works Committee, was joined by 32 Senators in introducing legislation that would put the United States on a path to achieve net-zero greenhouse gas emissions by no later than 2050.
Blog Post
Congress Introduces Bill to Protect Students with Asthma
Congress is taking steps to improve how schools across the country manage asthma. The federal bill is called the School-Based Asthma Management Programs Act (HR 4662). The bill encourages states to improve asthma care in schools. Schools that adopt improved asthma management programs and policies would have a better chance of receiving federal grant money for asthma programs. Representatives Phil Roe (R-TN) and Steny Hoyer (D-MD) are the sponsors of the bill. The bill calls for: stocking...
Blog Post
Congress Recognizes May as National Asthma and Allergy Awareness Month
The U.S. House of Representatives has declared their support for National Asthma and Allergy Awareness Month . Reps. Eliot Engel (D-NY), Fred Upton (R-MI), TJ Cox (D-CA) and Peter King (R-NY) submitted the resolution to the House Committee on Energy and Commerce on May 8, 2020. May is peak season for people with asthma and allergies. That’s why the Asthma and Allergy Foundation of America (AAFA) chose it as a time to raise awareness and educate people on how to manage these conditions. Read...
Blog Post
Dupilumab Shows Benefit for Those With Severe Asthma During Clinical Trial
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Phase 3 investigational study evaluating dupilumab in adults and adolescents with severe, steroid-dependent asthma met its primary endpoint and key secondary endpoints.
Blog Post
Dupixent® Shows Positive Results in Phase 3 of Trial for Ages 6 to 11 With Severe Atopic Dermatitis
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints. Dupixent is the first and only biologic to show positive results in this pediatric atopic dermatitis population.
Blog Post
Elijah E. Cummings Family Asthma Act Would Expand Efforts to Improve Care for People With Asthma
Representatives Eliot L. Engel (D-NY-16), Fred Upton (R-MI-06), Pete King (R-NY-02) and TJ Cox (D-CA-21), all members of the House Asthma and Allergy Caucus, have introduced legislation to honor Elijah E. Cummings’ long-time advocacy for those living with asthma. The Elijah E. Cummings Family Asthma Act would expand federal, state, and local efforts to improve care for individuals with asthma.
Blog Post
FDA Approves Dupixent® for Treatment of Asthma
The FDA has approved another biologic treatment, Dupixent, for the treatment of both moderate and severe asthma patients with eosinophilic phenotype
and oral corticosteroid-dependent asthma, regardless of phenotype.
Blog Post
FDA Approves Dupixent® for Moderate-to-Severe Atopic Dermatitis in Adolescents
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
Blog Post
February Advocacy Update: Over-the-Counter Medicines, Restaurant Safety and Cleaner Cars
Welcome to your February advocacy update. I’m Jenna Riemenschneider, director of advocacy at the Asthma and Allergy Foundation of America (AAFA). I am pictured above with AAFA board member Renuka Babu Brown and Senator Ed Markey's (D-MA) policy advisor Adam Axler. Over-the-Counter Drug Access and Cleaner Cars Rollbacks AAFA and other members of the Healthy Choices Coalition met with Representative Judy Chu's office. We asked her to co-sponsor the Restoring Access to Medication Act of 2019...
Blog Post
GlaxoSmithKline Recalls Two Lots of Ventolin HFA Albuterol Sulfate Inhalers
Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.
Blog Post
GlaxoSmithKline Study Shows Nucala Improves Quality of Life, Lung Function in Severe Asthma
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala® (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, when compared to patients treated with placebo and standard of care. These results are from the phase IIIb MUSCA study (NCT02281318, 200
Blog Post
GSK to Offer Generic Version of Ventolin HFA Albuterol Inhaler
The Asthma and Allergy Foundation of America is sharing this press release from GlaxoSmithKline to bring you the latest research news quickly. [PRESS RELEASE] GSK announces availability of Authorized Generic Albuterol Sulfate Inhaler for treatment or prevention of bronchospasm Effective, January 15, 2019, GSK announced the availability of an authorized generic (AG) of Ventolin HFA (albuterol sulfate) inhalation aerosol. The AG will be manufactured by GSK and distributed by Prasco LLC. The...
Blog Post
House Representatives Introduce Resolution to Have May Declared National Asthma and Allergy Awareness Month
To mark World Asthma Day, Representatives Eliot L. Engel (NY-16) and Fred Upton (MI-6) have introduced a bipartisan House Resolution designating the month of May as “National Asthma and Allergy Awareness Month.”
Blog Post
Please Don't Stop Your Asthma Medicines – An Editorial From Dr. Mitchell Grayson on the Coronavirus (COVID-19)
With the current spread of the new coronavirus (COVID-19) in the U.S. and around the world, many people with asthma wonder how it would affect them if they got the illness. There is a lot we still don't know about this illness. Dr. Mitchell Grayson, the chair of the Asthma and Allergy Foundation of America's (AAFA) Medical Scientific Council, wrote this article for our blog about what we do know at this time. There have been many questions about how having asthma affects your risk of getting...
Blog Post
Poverty Widens Gap in Care for Asthma and Allergies
Press Release Contact: Melissa Graham mgraham@aaaai.org (414) 272-6071 Onsite Press Room (March 4-7): (213) 743-6242 POVERTY WIDENS GAP IN CARE FOR ASTHMA AND ALLERGIES Researchers Examine Socioeconomic Disparities at AAAAI Annual Meeting Los Angeles, CA – Socioeconomic disparities are a cause for concern in patients with asthma and allergies, according to several studies presented at the AAAAI Annual Meeting. “We found that patients who have asthma and come from lower income households –...
Blog Post
School-Based Respiratory Health Management Act Introduced to House
[Press Release] Roe, Hoyer Introduce School-Based Respiratory Health Management Act Washington, May 2, 2017 | Lani Short (202-225-6356) WASHINGTON, DC – Today, Rep. Phil Roe, M.D. (R-TN) and House Democratic Whip Steny H. Hoyer (D-MD) introduced H.R. 2285, the School-Based Respiratory Health Management Act, legislation that encourages states to help ensure students with reversible lower airway disorders, such as asthma, have assistance at school with managing their chronic disease and can...
Blog Post
Schools and States Can Improve Indoor Air Quality for Students With Asthma and Allergies
As part of our 2019 State Honor Roll™ of Asthma and Allergy Policies for Schools (SHR), we look at the impact poor indoor air quality in schools can have on students with asthma and allergies.
Blog Post
Springfield, Massachusetts: Why It's the #1 Asthma Capital
Last year’s top Asthma Capital, Springfield, Massachusetts, is again the most challenging place in the U.S. to live with asthma. To get a better understanding of the asthma problem there, we talked with a local family, senator, allergist and city councilor.
Blog Post
Three Bills Could Have a Big Impact on People With Asthma and Allergies
May is National Asthma and Allergy Awareness Month . During this month, our community seeks to raise greater awareness with family, friends, coworkers and others about what it is like to live with asthma and allergies. It’s also a good time to engage with your elected officials in Congress about several pieces of legislation that improve access to asthma and allergy treatments and medicines, and protect the rights of our patient community. The Asthma and Allergy Foundation of America (AAFA)...
Blog Post
What You Need to Know About Medicare Drug Coverage If You Have Asthma and Allergies
If you have health insurance through Medicare, coverage for medicines is not automatic – you must sign up for a Medicare Part D plan. Here is what you need to know to enroll before the Dec. 7 deadline.
Blog Post
Hundreds Gather to Send Message to Congress About Climate Change
On July 13, 2017, Moms Clean Air Force hosted their fourth annual Play-In for Climate Action near the Capitol in Washington, D.C. The Asthma and Allergy Foundation (AAFA) was there to show support.
Blog Post
Ironman Cathy Tackles Asthma and Wins
Cathy Stephens was born not breathing. And since that day 47 years ago, breathing has periodically been a struggle for her. She shares her inspirational story of overcoming asthma to finish an Ironman triathlon.
Blog Post
Is It Really Asthma or Could It Be Something Else?
If you are on a treatment plan for asthma but the treatment doesn’t seem to be working, you might not have asthma. Or you may need a different type of asthma medicine. If you’ve been misdiagnosed, you might be trying to treat a condition you don’t have – and at the same time possibly ignoring a condition you really have.
Blog Post
LUSTER Clinical Trial Results for People With Uncontrolled Moderate-to-Severe Asthma Announced
Novartis today announced topline results from its pivotal global Phase III LUSTER-11 and LUSTER-22 studies exploring the efficacy and safety of the investigational oral, once-daily, DP2 receptor antagonist fevipiprant (QAW039). The pooled analyses of the LUSTER trials did not meet3 the clinically relevant threshold for reduction in rate of moderate-to-severe exacerbation compared to placebo over a 52-week treatment period for either of the doses (150mg / 450 mg).
Blog Post
Asthma Medication Recall Alert: Montelukast Tablets From Camber Pharmaceuticals for Incorrect Drug in Bottle
The U.S. Food and Drug Administration is warning consumers and health care professionals about a voluntary recall of one lot of Montelukast Sodium Tablets – lot number MON17384, expiration 12/31/2019 – by Camber Pharmaceuticals, Inc., Piscataway, N.J. Sealed bottles labeled as montelukast sodium tablets, 10 milligram, 30-count bottle from Camber were found to instead contain 90 tablets of Losartan Potassium Tablets, 50 mg.
Blog Post
November Asthma and Allergy Advocacy Update: School Protections and Emotional Support Animals and Epinephrine Auto-Injectors on Planes
Welcome to your November advocacy update. I’m Jenna Riemenschneider, Director of Advocacy at the Asthma and Allergy Foundation of America (AAFA).
Member
Myra D
Member
Karen D
Member
Steve D
Member
D. Sewell
Member
Jody D.
Member
Ana D. Cintron
Member
d
Member
D Miller
Member
Cathy D
Member
Mary D Travis
Comment
Re: GlaxoSmithKline Recalls Two Lots of Ventolin HFA Albuterol Sulfate Inhalers
I'm severely allergic to peanuts and cannot use proair. Pro air is manufacture it on the line that has peanut contamination. Whereas ventilon isn't. I am on social security and I cannot afford that price. However maybe it's the part D drug plan you have. If you were to change up you might be able to get it covered. Or your doctor should be getting samples .my doc provides me with samples .